A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged ≥12 Years
NCT05308602 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2024-02-09
Summary
The objective of the study is to evaluate the immunogenicity and safety of SCTV01C or SCTV01E, comparing the immunogenicity data against Beta (B.1.351), Delta (B.1.617.2), Omicron (B.1.1.529) and other variants with Sinopharm inactivated COVID-19 vaccine or mRNA vaccine.
Conditions
Interventions
- BIOLOGICAL
-
SCTV01C
Day 0; intramuscular injection
- BIOLOGICAL
-
SCTV01C
Day 28; intramuscular injection
- BIOLOGICAL
-
SCTV01C
Day 180; intramuscular injection
- BIOLOGICAL
-
SCTV01E
Day 0; intramuscular injection
- BIOLOGICAL
-
SCTV01E
Day 28; intramuscular injection
- BIOLOGICAL
-
SCTV01E
Day 180; intramuscular injection
- BIOLOGICAL
-
mRNA vaccine manufactured by Pfizer or Moderna
Day 0; intramuscular injection
- BIOLOGICAL
-
mRNA vaccine manufactured by Pfizer or Moderna
Day 28; intramuscular injection
- BIOLOGICAL
-
mRNA vaccine manufactured by Pfizer or Moderna
Day 180; intramuscular injection
- BIOLOGICAL
-
Sinopharm inactivated COVID-19 vaccine
Day 0; intramuscular injection
- BIOLOGICAL
-
Sinopharm inactivated COVID-19 vaccine
Day 28; intramuscular injection
- BIOLOGICAL
-
Sinopharm inactivated COVID-19 vaccine
Day 180; intramuscular injection
Sponsors & Collaborators
-
Sinocelltech Ltd.
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 12 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-04-01
- Primary Completion
- 2022-08-01
- Completion
- 2023-08-01
More Related Trials
-
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged ≥18 Years Previously Fully Vaccinated With mRNA COVID-19 Vaccine
NCT05238441 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged ≥18 Years and Previously Fully Vaccinated With COVID-19 Vaccine
NCT05238454 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 Years
NCT05345873 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines
NCT05323461 ·Status: UNKNOWN ·Phase: PHASE3
-
The Safety, Tolerability and Immunogenicity of COVID-19 Vaccine (SCTV01C) in Healthy, Unvaccinated Adults
NCT05148091 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)
NCT04352608 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With mRNA COVID-19 Vaccine.
NCT05043311 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine
NCT04833101 ·Status: COMPLETED ·Phase: PHASE4
-
The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine.
NCT05043285 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults
NCT05960097 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity and Safety of COVID-19 Vaccine as a Booster Vaccination in Population Aged 18 Years and Above
NCT05664932 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901 or MVC-COV1901(Beta) Against COVID-19
NCT05216601 ·Status: COMPLETED ·Phase: PHASE1
-
Sequential Immunization of Two Doses of Inactivated COVID-19 Vaccine (Omicron) in Vaccinated Population Aged 18 Years and Above
NCT05382871 ·Status: UNKNOWN ·Phase: PHASE3
-
Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
NCT04368728 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Safety and Immunogenicity of the RNA MCTI CIMATEC HDT Vaccine
NCT05542693 ·Status: UNKNOWN ·Phase: PHASE2
-
Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine
NCT05238649 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
NCT05997290 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and Above
NCT05381350 ·Status: COMPLETED ·Phase: PHASE3
-
A Study o Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901, CT-COV-21 Sub-study
NCT05038618 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19
NCT05197153 ·Status: COMPLETED ·Phase: PHASE2
-
Recombinant SARS-CoV-2 Fusion Protein Vaccine Booster Immunization Study to Evaluate the Safety and Immunogencity
NCT05239832 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants
NCT05004181 ·Status: COMPLETED ·Phase: PHASE2
-
Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults
NCT04617483 ·Status: COMPLETED ·Phase: PHASE3
-
A Heterologous Prime-boost Study to Evaluate Immunogenicity and Safety of mRNA-1273 With MVC-COV1901 in Adults
NCT05079633 ·Status: COMPLETED ·Phase: PHASE4
-
The Safety and Immunogenicity Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB002
NCT05928468 ·Status: UNKNOWN ·Phase: EARLY_PHASE1